Chronic opioid use is rare following radical prostatectomy in Europe. Slightly more than half of men undergoing RP in Sweden between 2007 and 2017 were found to have filled an opioid prescription, but the proportion who became chronic opioid users was less than 1%.
A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.
Patients with kidney stones who rank their pain at the maximum level on a 100-point scale or whose number-one goal for treatment is to relieve pain are less likely to reach their treatment goals than other patients undergoing kidney stone treatment, a recent study found.
A recent study found low levels of free testosterone in older men with prostate cancer could increase these men’s odds of facing erectile dysfunction after undergoing radical prostatectomy.
Urology Times interviewed four leading urologists who are experts in BPH to get their take on the most important BPH studies of 2018 and 2019.
A patient-reported outcomes survey that is widely used to determine whether men are experiencing erectile dysfunction (ED) fails to ask three critical questions that could uncover whether men truly have ED and the extent to which they face challenges, researchers say.
A study presented at the AUA annual meeting in Chicago shows higher rates of emergency department (ED) visits when ureteral access sheaths are used during ureteroscopy to remove kidney stones.
Forgotten stents are one of the most common challenges urologists and their patients face, and they can cause significant complications and increase costs of care. Now, a program that tracks stent insertion and removal in the electronic medical record shows strong potential to help eliminate retained stents.
High rates of residual fragments after ureteroscopy point to the need to both improve selection of patients for this procedure and find ways to boost stone-free rates, according to researchers at UT Southwestern Medical Center, Dallas.
As the number of patients who receive onabotulinumtoxinA (onabotA [Botox]) injections for overactive bladder increases, so does the age of this population and their associated comorbidities. This raises the question: Is the use of onabotA in patients who are taking anticoagulant or antiplatelet medication safe?